Prevention of mother-to-child transmission of HIV-1

Current Opinion in Obstetrics and Gynecology

Volumn 11, Issue 5, 1999, Pages 427-434

  Stringer, Jeffrey S A ^a   Vermund, Sten H ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; ZIDOVUDINE;

ARTIFICIAL MILK; BREAST FEEDING; CESAREAN SECTION; CLINICAL TRIAL; DISEASE ASSOCIATION; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MALNUTRITION; ORAL DRUG ADMINISTRATION; PATIENT SELECTION; PERINATAL INFECTION; PREGNANCY; PRIORITY JOURNAL; REVIEW; SURVIVAL; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

EID: 0032786893     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-199910000-00003     Document Type: Review

References (47)

1. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. New Engl J Med 1994; 331:1173-1180.
2. Anonymous. Recommendations of the US Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR 1994; 43:1-20.
3. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report 1997; 9:1-44.
4. UNAIDS/WHO, Report on the global HIV/AIDS epidemic: June 1998. [http://www.unaids.org/unaids/document/epidemio/june98/global_report/data/glo-br ep_e.pdf]. Accessed 21 May 1999.
5. McClure HM, Anderson DC, Fultz PN, Ansari AA, Jehuda-Cohen T, Villinger F, et al. Maternal transmission of SIVsmm in rhesus macaques. J Med Primatol 1991; 20:182-187.
6. Soeiro R, Rubinstein A, Rashbaum WK, Lyman WD. Maternofetal transmission of AIDS: frequency of human immunodeficiency virus type 1 nucleic acid sequences in human fetal DNA. J Infect Dis 1992; 166:699-703.
7. Brossard Y, Aubin J-T, Mandelbrot L, Bignozzi C, Brand D, Chaput A, et al. Frequency of early in utero HIV infection: a blind DNA polymerase chain reaction study on 100 fetal thymuses. AIDS 1995; 9:359-366.
8. Bryson YJ, Luzuriaga K, Sullivan JL, Wara DW. Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med 1992; 327:1246-1247.
9. Kreiss J. Breast feeding and vertical transmission of HIV-1. Acta Paediatr 1997; 421:113-117.
10. Fiscus SA, Adimora AA, Schoenbach VJ, Lim W, McKinney R, Rupar D, et al. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. JAMA 1996; 275:1483-1488.
11. Wade NA, Birkhead GS, Warren BL, Charbonneau TT, French PT, Wang L, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998; 339:1409-1414. Observational data from the New York State Department of Health that reports on the serological status of a cohort of 939 infants exposed to a variety of partial ZDV regimens.
12. Susser M. The prevention of perinatal HIV transmission in the less-developed world. Am J Pub Health 1998; 88:547-548.
13. Anonymous. Administration of zidovudine during late pregnancy and delivery to prevent perinatal HIV transmission - Thailand, 1996-1998. MMWR 1998; 47:151-154. The initial announcement of the results of the Thai/CDC short-course ZDV trial.
14. Shaffer N, Chuachoowong R, Mock PA, Siriwasin C, Young W, Chotpitayasunondh NL, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomized controlled trial. Lancet 1999; 353:773-780. The full paper on the Thai/CDC short-course ZDV trial. Discussed at length in text.
15. Debis F, Msellati P, Meda N, Welffens-Ekra C, You B, Manigard O, et al. Six-month efficacy, tolerance, and acceptability eta short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet 1999; 353:786-792. A randomized trial of short-course ZDV conducted in Africa and in breast-feeding women. Women were also treated with ZDV for 1 week postpartum. Discussed at length in text.
16. Wiktor SZ, Ekpini E, Karon JM, Nkengasong J, Maurice C, Severin ST, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomized trial. Lancet 1999; 353:781-785. Another randomized trial of short-course ZDV conducted in Africa and in breast-feeding women. Discussed at length in text.
17. Saba J. The results of the PETRA intervention trial to prevent perinatal transmission in sub-Saharan Africa. 6th Conference on Retroviruses and Opportunistic Infections, 31 January-4 February 1999. Chicago, IL. [http://www.retroconference.org/99/lect_symposia/sym_session8.html.] Accessed 18 May 1999. A large trial of short-course, combination ZDV-3TC conducted in breast-feeding women in Africa. The definitive, peer-reviewed paper is highly anticipated.
18. Fang G, Burger H, Grimson R, Tropper P, Nachman S, Mayers D, et al. Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission. Proc Natl Acad Sci USA 1995; 92:12100-12104.
19. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trial Group 320 Study Team. N Engl J Med 1997; 337:725-733.
20. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734-739.
21. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
22. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society - USA Panel. JAMA 1998; 280:78-86. An excellent review of the current state of antiretroviral therapy in HIV-infected patients.
23. Centers for Disease Control and Prevention. Public Health Service task force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR 1998; 47:1-30. Important CDC recommendations for antiretroviral therapy in pregnant women. Includes case scenarios and other specific management strategies.
24. Birchard K. Ireland's success with HIV pregnancies. Lancet 1998; 352:796.
25. O'Sullivan MJ, Scott G, Yasin S, Mitchell C, Scott W, Duthely M. Protease inhibitors: is preterm delivery a risk? Am J Obstet Gynecol 1999; 180:S105, Abstract 353.
26. Stek A, Kramer F, Fassett M, Khoury M. The safety and efficacy of protease inhibitor therapy for HIV infection during pregnancy. Am J Obstet Gynecol 1999; 180:S7, Abstract 14.
27. Morris A, Zorrilla C, Vajaranant M, Dobles A, Cu-uvin S, Jones T, et al. A review of protease inhibitor (PI) use in 89 pregnancies, In: Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, 31 January-4 February 1999. Chicago, IL. [http:\\www.retroconference.org. Abstract 686.]
28. Dunn DT, Newell M-L, Mayaux MJ, Kind C, Hutto C, Goedert JJ, et al. Mode of delivery and vertical transmission of HIV-1: a review of prospective studies. J Acquired Immune Defic Syndr Human Retrovirol 1994; 7:1064-1066.
29. Andiman W, Boucher M, Burns D, Bryson Y, Farley J, Fowler H, et al. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1 - a mete-analysis of 15 prospective cohort studies. The International Perinatal HIV Group. N Engl J Med 1999; 340:977-987.
30. The European Mode of Delivery Collaboration. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomized clinical trial, Lancet 1999; 353; 1035-1039. An important clinical trial conducted in Europe, in which HIV-infected gravidas were randomly assigned to either elective (pre-labor, pre-membrane rupture) cesarean or attempted vaginal delivery, Discussed at length in text.
31. Semprini AE, Castagna C, Ravizza M, Fiore S, Savasi V, Muggiasca ML, et al. The incidence of complications after cesarean section in 156 HIV-positive women. AIDS 1995; 9:913-917.
32. Stringer JSA, Rouse DJ, Goldenberg RL. Prophylactic cesarean delivery for the prevention of perinatal human immunodeficiency virus transmission: the case for restraint, JAMA 1999; 281:1946-1949.
33. UNAIDS. HIV and infant feeding: a policy statement developed collaboratively by UNAIDS, UNICEF, and WHO. [http://www.unaids.org/unaids/document/mother-to-child/infant.html]. Accessed 21 May 1999.
34. Case DE, McAntish J, Rushton A, Winrow MJ. Chlorhexidine: attempts to detect percutaneous absorption in man. Proceedings of the 9th International Congress of Chemotherapy 1987; 3:364-367.
35. Harrison C, Chantler E. The effect of nonoxynol-9 and chlorhexidine on HIV and sperm in vitro, Int J STD AIDS 1998; 9:92-97.
36. Harbison MA, Hammer SM. Inactivation of human immunodeficiency virus by Betadine products and chlorhexidine. J AIDS 1989; 2:16-20.
37. Biggar RJ, Miotti PG, Taha TE, Mtimavalye L, Broadhead R, Justesen A, et al. Perinatal intervention trial in Africa: effect of a birth canal cleansing intervention to prevent HIV transmission. Lancet 1996; 347:1647-1650.
38. Taha TE, Biggar RJ, Broadhead RL, Mtimavalye LA, Justesen AB, Liomba GN, et al. Effect of cleansing the birth canal with antiseptic solution on maternal and newborn morbidity and mortality in Malawi: clinical trial, BMJ 1997; 315:216-220.
39. Semba RD, Miotti PG, Chiphangwi JD, Henderson R, Dallabetta G, Yang LP, Hoover D. Maternal vitamin A deficiency and mother-to-child transmission of HIV-1. Lancet 1994; 343:1593-1597.
40. Semba RD. Overview of the potential role of vitamin A in mother-to-child transmission of HIV-1. Acta Paediatr 1997; 421:107-112.
41. Fawzi WW, Hunter DJ. Vitamins in HIV disease progression and vertical transmission, Epidemiology 1998; 9:457-466.
42. Baum MK, Shor-Posner G, Lai S, Zhang G, Lai H, Fletcher MA, et al. High risk of HIV-related mortality is associated with selenium deficiency. J Acquired Immune Defic Syndr Human Retrovirol 1997; 15:370-374.
43. Andrews WW, Goldenberg RL, Hauth JC. Preterm labor: emerging role of genital tract infections. Infect Agents Dis 1995; 4:196-211.
44. Goldenberg RL, Vermund SH, Goepfert AR, Andrews WW. Choriodecidual inflammation: a potentially preventable cause of perinatal HIV-1 transmission? Lancet 1998; 352:1927-1930.
45. New York State Department of Health. HIV/AIDS Quarterly Update, 1998; [http://www.health.state.ny.us/nysdoh/aids/december1998/main.htm,Tables4aand7]. Accessed 21 May 1999.
46. Institute of Medicine, Committee on Perinatal Transmission of HIV. Recommendations. In: Reducing the odds: preventing perinatal transmission of HIV in the United States. Stoto MA, Alamrio DA, McCormick MC (editors). Washington, DC: National Academy Press; 1999. pp. 109-133. A recently published volume from the Institute of Medicine on the state of perinatal HIV transmission in the United States. This publication is of special interest to both policy makers and clinicians interested in developing HIV prevention strategies.
47. The National Institute of Allergy and Infectious Diseases. Press release. HIVNET012 Executive Summary 1999; http://www.niaid.nih.gov/newsroom/simple/exec.htm.